Cargando…
Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options
Acetaminophen is an extremely common drug with many implications for its analgesic and antipyretic properties. It has a unique mechanism of action and downstream effects that separate it categorically from non-steroidal anti-inflammatory drugs. These differences come with potential adverse effects t...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382713/ https://www.ncbi.nlm.nih.gov/pubmed/37519510 http://dx.doi.org/10.7759/cureus.41116 |
_version_ | 1785080732726591488 |
---|---|
author | Spillers, Noah J Luther, Patrick M Talbot, Norris C Ly, Gianni H Downs, Evan M Lavespere, Gabriel Pavlickova, Denisa Ahmadzadeh, Shahab Viswanath, Omar Varrassi, Giustino Shekoohi, Sahar Kaye, Alan D |
author_facet | Spillers, Noah J Luther, Patrick M Talbot, Norris C Ly, Gianni H Downs, Evan M Lavespere, Gabriel Pavlickova, Denisa Ahmadzadeh, Shahab Viswanath, Omar Varrassi, Giustino Shekoohi, Sahar Kaye, Alan D |
author_sort | Spillers, Noah J |
collection | PubMed |
description | Acetaminophen is an extremely common drug with many implications for its analgesic and antipyretic properties. It has a unique mechanism of action and downstream effects that separate it categorically from non-steroidal anti-inflammatory drugs. These differences come with potential adverse effects that range from mild drug reactions to severe life-threatening emergencies. While acetaminophen's toxic liver effects are well known, a lesser-known adverse effect of this drug is its association with the development of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These dermatological emergencies involve similar pathological processes, including apoptosis of the epidermis and sloughing of the dermis and mucosa from the underlying layers with a positive Nikolsky sign. Currently, SJS and TEN are considered immune-mediated type IV hypersensitivity reactions predominantly involving CD8+ T lymphocytes. Other immune mediators, including regulatory T cells, natural killer cells, interleukins, and drug metabolites are speculated to be involved, but their mechanisms have not been entirely determined. These conditions are differentially diagnosed by the percentage of body area affected with SJS and TENS, involving <10% and >30%, respectively. Genomic variations in human leukocyte antigens (HLA) genes have been implicated in the susceptibility and severity of acetaminophen-induced SJS/TENS, however, details of these interactions remain unclear. Acetaminophen’s widespread use and the morbidity of its associated skin pathologies SJS and TENS warrant an in-depth examination of the causative processes involved in their pathogenesis. It is critical that both physicians and patients be made aware that while acetaminophen is widely tolerated by most individuals, severe and potentially fatal interactions do occur, and further investigation is necessary to reduce these adverse effects. |
format | Online Article Text |
id | pubmed-10382713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-103827132023-07-30 Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options Spillers, Noah J Luther, Patrick M Talbot, Norris C Ly, Gianni H Downs, Evan M Lavespere, Gabriel Pavlickova, Denisa Ahmadzadeh, Shahab Viswanath, Omar Varrassi, Giustino Shekoohi, Sahar Kaye, Alan D Cureus Dermatology Acetaminophen is an extremely common drug with many implications for its analgesic and antipyretic properties. It has a unique mechanism of action and downstream effects that separate it categorically from non-steroidal anti-inflammatory drugs. These differences come with potential adverse effects that range from mild drug reactions to severe life-threatening emergencies. While acetaminophen's toxic liver effects are well known, a lesser-known adverse effect of this drug is its association with the development of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These dermatological emergencies involve similar pathological processes, including apoptosis of the epidermis and sloughing of the dermis and mucosa from the underlying layers with a positive Nikolsky sign. Currently, SJS and TEN are considered immune-mediated type IV hypersensitivity reactions predominantly involving CD8+ T lymphocytes. Other immune mediators, including regulatory T cells, natural killer cells, interleukins, and drug metabolites are speculated to be involved, but their mechanisms have not been entirely determined. These conditions are differentially diagnosed by the percentage of body area affected with SJS and TENS, involving <10% and >30%, respectively. Genomic variations in human leukocyte antigens (HLA) genes have been implicated in the susceptibility and severity of acetaminophen-induced SJS/TENS, however, details of these interactions remain unclear. Acetaminophen’s widespread use and the morbidity of its associated skin pathologies SJS and TENS warrant an in-depth examination of the causative processes involved in their pathogenesis. It is critical that both physicians and patients be made aware that while acetaminophen is widely tolerated by most individuals, severe and potentially fatal interactions do occur, and further investigation is necessary to reduce these adverse effects. Cureus 2023-06-28 /pmc/articles/PMC10382713/ /pubmed/37519510 http://dx.doi.org/10.7759/cureus.41116 Text en Copyright © 2023, Spillers et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Dermatology Spillers, Noah J Luther, Patrick M Talbot, Norris C Ly, Gianni H Downs, Evan M Lavespere, Gabriel Pavlickova, Denisa Ahmadzadeh, Shahab Viswanath, Omar Varrassi, Giustino Shekoohi, Sahar Kaye, Alan D Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options |
title | Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options |
title_full | Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options |
title_fullStr | Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options |
title_full_unstemmed | Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options |
title_short | Association of Acetaminophen With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Pharmacologic Considerations and Treatment Options |
title_sort | association of acetaminophen with stevens-johnson syndrome and toxic epidermal necrolysis: pharmacologic considerations and treatment options |
topic | Dermatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10382713/ https://www.ncbi.nlm.nih.gov/pubmed/37519510 http://dx.doi.org/10.7759/cureus.41116 |
work_keys_str_mv | AT spillersnoahj associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT lutherpatrickm associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT talbotnorrisc associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT lygiannih associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT downsevanm associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT lavesperegabriel associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT pavlickovadenisa associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT ahmadzadehshahab associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT viswanathomar associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT varrassigiustino associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT shekoohisahar associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions AT kayealand associationofacetaminophenwithstevensjohnsonsyndromeandtoxicepidermalnecrolysispharmacologicconsiderationsandtreatmentoptions |